Odonate, Inc.

ODT

US6760793041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:05:58 2024-04-16 pm EDT			5-day change	1st Jan Change
15,900 ^USD	+2.45%		+2.45%	+6.00%

2023	North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	DJ
2023	North American Morning Briefing : Stock Futures -2-	DJ

Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from Russell 2000 Growth Index

June 25, 2021 at 12:00 am EDT

Latest news about Odonate, Inc.

North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23-06-23	DJ
North American Morning Briefing : Stock Futures -2-	23-06-16	DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks	23-06-09	DJ
North American Morning Briefing : Stock Futures -2-	23-06-02	DJ
North American Morning Briefing : Investors Await -2-	23-05-26	DJ
North American Morning Briefing : Powell on Tap -2-	23-05-19	DJ
North American Morning Briefing : Hopes of Easing -2-	23-05-12	DJ
North American Morning Briefing : Caution -2-	23-04-14	DJ
North American Morning Briefing : Stock Futures -2-	22-05-20	DJ
North American Morning Briefing : Tech Futures -2-	22-05-13	DJ
North American Morning Briefing : Stocks Waver, -3-	22-04-12	DJ
North American Morning Briefing : Stocks to Open -3-	22-02-22	DJ
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index	22-01-20	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index	22-01-20	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Composite Index	22-01-17	CI
Top Midday Decliners	22-01-07	MT
Odonate Therapeutics Gets Nasdaq Notice to Delist Shares	22-01-07	MT
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Biotechnology Index	21-12-17	CI
Insider Sell: Odonate Therapeutics	21-11-22	MT
Odonate Therapeutics Plans Share Buybacks After Halting Development of Breast Cancer Drug	21-11-17	MT
Odonate Therapeutics, Inc. announces an Equity Buyback for 20,000,000 shares, representing 51.95% of its issued share capital.	21-11-17	CI
Odonate Therapeutics, Inc. authorizes a Buyback Plan.	21-11-16	CI
Odonate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
North American Morning Briefing : Stock Futures -3-	21-11-10	DJ
Odonate Therapeutics, Inc. Announces Termination of Joseph O’Connell as Chief Medical Officer	21-08-05	CI

Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ODONATE, INC.	+6.00%	45.16M
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals

Odonate, Inc.

Equities

ODT

US6760793041

Pharmaceuticals

Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from Russell 2000 Growth Index

Latest news about Odonate, Inc.

Chart Odonate, Inc.

Company Profile

Sector Other Pharmaceuticals